Madrigal Pharmaceuticals, Inc.
Every calculator, already run for MDGL
Open the full toolkit →You have the numbers on MDGL. Get the argument.
A written report on which of these readings actually decide the outcome for Madrigal Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
17 analysts covering MDGLOwnership & short interest
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
MDGL — frequently asked
Is MDGL a buy right now?
Wall Street's consensus rating on Madrigal Pharmaceuticals, Inc. is Strong Buy across 17 analysts, with a mean price target of $682.93 (+33% vs. the current $513.84). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Compare Madrigal Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Madrigal Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full MDGL research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Madrigal Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.